Hundreds Sue Pfizer Over Birth Control Jabs Linked to Brain Tumors

American pharmaceutical and biotech company Pfizer has been sued by hundreds of American and UK women after a recent study revealed that a contraceptive injection developed by the company increased their risk of developing brain tumors significantly. Four hundred American women have already filed the lawsuit in a Florida county, and around 200 women from the UK are also considering suing the pharmaceutical firm, the Daily Mail reports.

According to Virginia Buchanan, a partner at Florida-based law firm Levin Papantonio, the U.S. lawsuit will help the American plaintiffs receive justice after Pfizer failed to warn them of the elevated brain tumor risks associated with its birth control jab. With hundreds of thousands of women receiving contraceptive injections in the U.S., more American women who received the Pfizer injection may join the lawsuit over the next couple of weeks.

In the UK, the National Health Service (NHS) estimates that around 10,000 have contraceptive injections every year, indicating that a decent portion of UK women may also have received the Pfizer injection without adequate warnings about the treatment’s brain cancer risks. A study by the National Agency for Medicines and Health Products Safety in France found that although the medication doesn’t increase the risk of cancerous brain tumors, it can still lead to meningioma, which can cause severe injury or even death by compressing nerves and brain tissue.

Once the study’s findings were made public, the Medicines and Healthcare Products Regulatory Agency, a regulatory body that ensures the safety of medications and medical devices in the UK, began warning users about the risks associated with Pfizer’s contraceptive injections via information leaflets. Additionally, Pfizer issued a warning to physicians and advised them to stop providing Depo-Provera jabs to patients with a meningioma diagnosis.

French researchers analyzed data collected from over 18,000 women who had gone through surgery to treat meningioma from 2009 to 2018. The team discovered that women who received Depo-Provera injections were five times more likely to develop meningioma, a tumor that typically originates from the meninges, a set of three membranes that enclose and protect the spinal cord and brain.

Meningioma technically isn’t classified as a brain tumor, but it is the most common tumor that forms in the head, and it can cause neurological symptoms such as memory loss and seizures by pressing on the brain, blood vessels, and nerves.

Prior research also found that combined birth control pills that comprise both progesterone and estrogen can increase the risk of developing meningioma by 20%. Contraceptive and coil implants have also been found to increase the risk of the disease at similarly elevated rates. The French study also noted that modern oral hormonal contraceptives are just as risky, with the most recent progesterone-only contraceptive pill increasing breast cancer risks by around 20–30%.

As efforts are undertaken by firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to develop new treatments against central nervous system cancers, it is imperative that further research is done to identify factors that predispose women and other groups of people to tumor development and awareness is created in the public so that avoidable contributing factors can be sidestepped whenever possible in order to reduce the disease burden.

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN